Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors

Neoplasia. 2024 Apr:50:100974. doi: 10.1016/j.neo.2024.100974. Epub 2024 Feb 16.

Abstract

Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, myeloma cells have acquired functional capabilities which are referred to as "Hallmarks of Cancer", and one of their most important features is the metabolic disorders. Due to the high secretory load of the MM cells, the first-line medicine proteasome inhibitors have found their pronounced effects in MM cells for blocking the degradation of misfolded proteins, leading to their accumulation in the ER and overwhelming ER stress. Moreover, proteasome inhibitors have been reported to be effective in myeloma by targeting glucose, lipid, amino acid metabolism of MM cells. In this review, we have described the abnormal metabolism of the three major nutrients, such as glucose, lipid and amino acids, which participate in the cellular functions. We have described their roles in myeloma progression, how they could be exploited for therapeutic purposes, and current therapeutic strategies targeting these metabolites, hoping to uncover potential novel therapeutic targets and promote the development of future therapeutic approaches.

Keywords: Cancer metabolism; Multiple myeloma; Warburg effect.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Glucose
  • Humans
  • Lipids / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / metabolism
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors* / pharmacology
  • Proteasome Inhibitors* / therapeutic use

Substances

  • Proteasome Inhibitors
  • Glucose
  • Lipids
  • Proteasome Endopeptidase Complex